

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

39-187

SERIAL NO.

09/367,261

APPLICANT

BLAKE et al

(Use several sheets if necessary)

FILING DATE

August 13, 1999



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
B71	5 0 8 6 0 6 8	2/1992	Raleigh et al			
B71	5 3 8 7 6 9 2	2/1995	Riley et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
0 6 5 0 7 6 3	6/1995	EP			
WO 96 25147	8/1996	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, etc.)

B71	1	Oellinger et al, "Study on the redox properties of naphthazarin (5,8-dihydroxy-1,4-naphthoquinone) and its glutathionyl conjugate in biological reactions: one- and two-electron enzymic reduction", <i>CHEMICAL ABSTRACTS</i> , VOL. 112, NO. 11, 12 March 1990, Columbus, Ohio, US; and <i>ARCH. BIOCHEM. BIOPHYS.</i> (1989).
		Firestone et al, "Nitro heterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells", <i>J. MED. CHEM.</i> (1991), 34(9).
		Chikhale et al, "Tumor targeted prodrugs: Redox-activation of conformationally constrained, bioreductive melphalan prodrugs", <i>EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH</i> , San Diego, California, USA, April 12-16, 1997. <i>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING</i> (38 (0). 1997. 432-433.
		Mehta et al, "Potential bioreductively activated hypoxia probes and post-irradiation radiosensitizers related to NITP", <i>ANTI-CANCER DRUG DES.</i> (1995), 10(3), 227-41.
		Hodgkiss et al, "Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration", <i>BR. J. CANCER</i> , vol. 72, 1995, pages 1462-1468.
B71		Berglund, "Bioreductive Heterosubstituted Quinone Antitumor Drug Delivery Agents", <i>DATABASE DISSABS</i> , 1987.

*Examiner B. D. D. D. Date Considered 6-23-2006

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

C9/367261

Sheet 1 of 1

510 Rec'd PCT/PTO 13 AUG 1999

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

39-187

SERIAL NO.

Unknown

APPLICANT

BLAKE et al

(Use several sheets if necessary)

FILING DATE

GROUP

August 13, 1999

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BP	5 0 8 6 0 6 8	2/1992	Raleigh et al			
BP	5 3 8 7 6 9 2	2/1995	Riley et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
0 659 763	6/1995	EP			
WO 96 25147	8/1996	PCT			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

BP	Oellinger et al, "Study on the redox properties of naphthazarin (5,8-dihydroxy-1,4-naphthoquinone) and its glutathionyl conjugate in biological reactions: one- and two-electron enzymic reduction", <i>CHEMICAL ABSTRACTS</i> , VOL. 112, NO. 11, 12 March 1990, Columbus, Ohio, US; and <i>ARCH. BIOCHEM. BIOPHYS.</i> (1989).
	Firestone et al, "Nitro heterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells", <i>J. MED. CHEM.</i> (1991), 34(9).
	Chikhale et al, "Tumor targeted prodrugs: Redox-activation of conformationally constrained, bioreductive melphalan prodrugs", <i>EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH</i> , San Diego, California, USA, April 12-16, 1997. <i>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING</i> (38 (0). 1997. 432-433.
	Mehta et al, "Potential bioreductively activated hypoxia probes and post-irradiation radiosensitizers related to NITP", <i>ANTI-CANCER DRUG DES.</i> (1995), 10(3), 227-41.
	Hodgkiss et al, "Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration", <i>BR. J. CANCER</i> , vol. 72, 1995, pages 1462-1468.
BP	Berglund, "Bioreductive Heterosubstituted Quinone Antitumor Drug Delivery Agents", <i>DATABASE DISSABS</i> , 1987.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)